Clinical characteristics from the individual studies for RA related pulmonary disease included in the metaanalysis.
| First Author | Year | DAS28, Mean (range)& | CRP, mg/l, Mean (range)& | RF Positivity, n (%)& | Smoking History, n (%)& | Using MTX, n (%)& | Using Biologic Agents, n (%)& | Using Steroids, n (%)& |
|---|---|---|---|---|---|---|---|---|
| Giles | 2013 | 3.8 (3.2–4.4)/3.5 (2.8–4.3) | 3.5 (1.2–8.4)/2.3 (1.0–7.1) | 43 (75.0)/71 (59.0)# | 43 (75.0)/63 (53.0)# | 33 (58.0)/81 (68.0) | 33 (58.0)/49 (41.0)# | 29 (51.0)/38 (32.0)# |
| Mori-ILD* | 2012 | NA | NA | 23 (95.8)/225 (74.5)# | 11 (45.8)/62 (20.5)# | 3 (12.5)/37 (12.3) | 0 (0)/1 (0.3) | NA |
| Mori-AD* | 2012 | NA | NA | 26 (86.7)/225 (74.5) | 3 (10.0)/62 (20.5) | 4 (13.3)/37 (12.3) | 0 (0)/1 (0.3) | NA |
| Jearn | 2012 | NA | NA | NA | NA | NA | NA | NA |
| Aubart | 2011 | NA | NA | 48 (82.0)/134 (69.6) | 20 (33.2)/65 (33.9) | 32 (54.2)/120 (62.2) | 20 (33.9)/58 (30.1) | NA |
| Skare | 2011 | NA | NA | 19 (76.0)/31 (70.4) | 9 (37.5)/16 (36.3) | 14 (58.3)/31 (72) | 4 (14.8)/3 (6.8) | NA |
| Inui | 2008 | NA | 22 (13–32)/22 (7–43) | NA | 12 (66.7)/11 (30.6)# | NA | NA | NA |
| Alexiou | 2008 | NA | NA | NA | NA | NA | NA | NA |
↵* One study contained detailed data regarding the relationships between serum ACPA positivity and the risks of ILD and AD separately.
↵& Comparison of cases and controls.
↵# p < 0.05. ILD: interstitial lung disease; AD: airway disease; IPF: interstitial pulmonary fibrosis; BC: bronchiectasis; RN: rheumatoid nodules; RPPL: reticular pattern pulmonary lesions; PD: pulmonary disease; RA: rheumatoid arthritis; W: white; A: Asian; ACPA: anticitrullinated protein antibody; P: positive; N: negative; NOS: Newcastle-Ottawa Scale; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; RF: rheumatoid factor; MTX: methotrexate; NA: not available.